Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Morgan Stanley

Equities research analysts at Morgan Stanley assumed coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Morgan Stanley’s target price indicates a potential upside of 129.36% from the company’s current price.

Several other equities research analysts have also recently issued reports on the stock. Citizens Jmp assumed coverage on shares of Immix Biopharma in a research report on Monday, March 9th. They issued an “outperform” rating and a $23.00 price objective for the company. Mizuho assumed coverage on shares of Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 price target for the company. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immix Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

Immix Biopharma Trading Down 2.1%

Shares of IMMX opened at $8.72 on Wednesday. The firm has a fifty day moving average price of $7.70 and a 200-day moving average price of $5.20. The firm has a market capitalization of $461.81 million, a P/E ratio of -9.80 and a beta of 0.25. Immix Biopharma has a 12-month low of $1.34 and a 12-month high of $11.61.

Institutional Investors Weigh In On Immix Biopharma

Several large investors have recently modified their holdings of the business. XTX Topco Ltd lifted its position in shares of Immix Biopharma by 32.0% in the 4th quarter. XTX Topco Ltd now owns 46,394 shares of the company’s stock worth $243,000 after purchasing an additional 11,241 shares during the period. CIBC Private Wealth Group LLC increased its holdings in Immix Biopharma by 300.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 40,000 shares of the company’s stock valued at $209,000 after buying an additional 30,000 shares during the period. Barclays PLC bought a new position in Immix Biopharma in the fourth quarter worth approximately $183,000. Persistent Asset Partners Ltd purchased a new stake in Immix Biopharma during the fourth quarter worth $166,000. Finally, Quadrature Capital Ltd purchased a new stake in Immix Biopharma during the fourth quarter worth $116,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.